Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Concordia Healthcare Corp. T.CXR.R

TSX:CXR.R - Post Discussion

Concordia Healthcare Corp. > Cinven payment = Amco Performance
View:
Post by cg16 on Oct 15, 2016 12:06pm

Cinven payment = Amco Performance

Its difficult to follow script data accurately on Amco. But if the Cinven earnout payment is tied to performance, wouldn't having to pay it be the best indication that scripts are fine? There's no worry that CXR has the money to pay the December payment (I think everyone can agree to that), so for me, its whether or not they actually have to pay it that matters most. Lots coming down at this next Quarterly report it seems.
Comment by Lumberfeverlong on Oct 15, 2016 12:11pm
Great point. Yes having to make the Cinven payments is a good indication of positive performance of the Amco portfolio.
Comment by cg16 on Oct 15, 2016 12:28pm
I try to follow RBC's reports on US scripts, but need to see Q3 reported to see if the write down was appropriate (some analysts question if it was too big and Shorts believe it was too little). It does seem that Donnatal is holding at 1.65% share. It makes sense that it won't erode much further because its only 1.65% of the patients that can't live without it. Not sure its worth it to ...more  
Comment by LaticelnExile on Oct 15, 2016 12:40pm
This post has been removed in accordance with Community Policy
Comment by LaticelnExile on Oct 15, 2016 12:22pm
This post has been removed in accordance with Community Policy
Comment by GOODNEWZ on Oct 15, 2016 12:31pm
The international revenues continue to be very strong.   Don't trust fabrications from these US-based short bashers using boiler room tricks to fool investors. The CEO will start buying here at these lows and this stock will take off!
Comment by cg16 on Oct 15, 2016 12:38pm
Lat, thanks for the info but I'm not following you? Are you saying that CXR will not have to make the payment because of significant drop in sales in Q3 ("after June")? Or are you saying that even though sales are significantly hampered in Q3, the performance threshold is still reached and payment will occur?
Comment by LaticelnExile on Oct 15, 2016 12:58pm
This post has been removed in accordance with Community Policy
Comment by Craigbad on Oct 15, 2016 1:20pm
Another theory is there was channel stuffing in the UK. If the numbers were met to trigger the earnout, they should have had the cashflow to make the payment. If the product was stuffed in channels the cashflow wouldn't be there. Why else would they issue high interest notes to pay high interest debt? When you take Goldman and Greenhills cut out of the $350 million the interest rate is much ...more  
Comment by cg16 on Oct 15, 2016 2:09pm
Just want to clarify: Craig, your new theory is that CXR stuffed the UK channel so they would have to make a payment that they really shouldn't owe? Why would they do that? I would be surprised if management was still looking to convert the Cinven payment to equity at the recent prices. That would mean 20-30 million new shares for the sake of a $180m payment? Thats more desperate than the ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities